Skip to main content
OpenTrials
Completed

NCT Number: NCT05574790

Identification of Multimorbid Patients With a Higher Probability of Readmission and Mortality

A prospective qualitative quantitative study was designed to create predictive models of readmission in multimorbid patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Galdakao Usansolo, Galdakao, Bizkaia, Spain

Loading trial locations.

About this study

Social determinants have been shown to be related to the probability of readmission and death in multimorbid patients. These are increasingly older, which makes them more likely to be readmitted when their preferences are usually to be at home. Objective: To create and validate prediction models for readmission and mortality during home transitional period (1 month) and up to a year, in multimorbid patients, including variables related to the patient and their social environment. Design: Quali-quantitative. 4 hospitals from 3 regions (Andalucia, Catalonia and the Basque Country) will participate . Patients presenting at least 2 of the Ollero's categories will be included. Variables will be identified by means of nominal groups of professionals and focal groups with patients and caregivers. These variables will be included in the final models join to clinical variables, PROMS (health related quality of life, burden of the caregiver , social support). Logistic/ Cox regression models will be developed and validated internally to identify the risk of readmission and death which will be validated in an external cohort. Expected results: We hope to provide the health system with stratification tools for polypathological patients that help in identifying those patients with the greatest need for individualized interventions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18 years of age
  • Patients discharged from the Internal Medicine departments of the participating centers due to acute pathology, de novo or decompensation of a chronic pathology who also present at least 2 of the cathegories of Ollero et al.

Exclusion criteria

  • Patients admitted for end-of-life treatment, scheduled admissions, exacerbation of rheumatic pathology or systemic disease, study of anaemia in patients with no-known comorbidity, search for neoplasia and acute processes without associated comorbidity. -
  • Failure to sign the informed consent form.

Treatment and study plan

annual follow up

Other

Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality

Primary outcomes

  1. Readmission

    Time frame: 1 month

    number of readmissions in the early period (transition to discharge, 1 month

  2. Readmission

    Time frame: 1 year

    number of readmissions in the annual period

Sponsors and collaborators

Lead sponsor

Hospital Galdakao-Usansolo

Other Gov

Collaborators

  • Asociacion Instituto de Investigacion en Servicios de Salud Kronikgune
  • Hospital Costa del Sol
  • Hospital del Mar
  • Hospitales Universitarios Virgen del Rocío
  • Instituto de Salud Carlos III

Registry information

Official study title

Identification of Multimorbid Patients With a Higher Probability of Readmission and Mortality: Role of Patient-related Variables

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Oct 12, 2022
Registry last updated
Sep 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.